Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

FDA rejects Allergan’s uterine fibroid drug over safety concerns

Its investigational drug has been linked to 'serious' liver damage issues in Europe

- PMLiVE

Ashfield Digital & Creative win IMA award, Lucid SPIRIT selects charity partner and Dovetail to pilot collaborative workshops

The latest in med comms

- PMLiVE

John Czekanski leaves Fishawack, dna adds to team and Porterhouse announces promotions

The latest med comms movers

- PMLiVE

AbbVie to develop argenx-partnered GARP-targeted immunotherapy

Will build on an initial $60m deal with the biotech

- PMLiVE

Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

The latest industry movers

- PMLiVE

Novo’s oral diabetes drug hits the mark again

The drug proves effective in reducing blood sugar in diabetes patients with renal impairment

AstraZeneca AZ

AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

Japanese regulator clears the drug for first-line use in NSCLC

- PMLiVE

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

Becomes the first checkpoint inhibitor for this indication

- PMLiVE

Envision Pharma Group relocates to support growth

Expands its Horsham to accommodate for additional team members

- PMLiVE

Evoke Group unveils new identity

Rebrands to help clients better navigate the healthcare landscape

The European Medicines Agency: PRIME’d for access?

Leela Barham examines the impact of the EMA's PRIME fast track system after two years

- PMLiVE

Roche’s Alecensa backed by China’s National Drug Administration

Approved to treat ALK-positive lung cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links